Clinical Trial

Trial of INI-4001 in Patients With Advanced Solid Tumours

Name: Trial of INI-4001 in Patients With Advanced Solid Tumours — clinical trial record (NCT06302426)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

Phase 1 open-label, dose-escalation and dose-expansion study of INI-4001 as a single agent and in combination with approved checkpoint inhibitors in subjects with advanced solid tumors.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2024-03-04.

Status change: Not Yet Recruiting → Recruiting 2026-01-15

Trial Details

NCT Number	NCT06302426
Lead Sponsor	Inimmune Corporation Collaborators: Avance Clinical Pty Ltd.
Conditions	Advanced Solid Tumor
Enrollment	50 participants
Start Date	2024-07-01
Primary Completion	2026-10-30 (estimated)
Study Completion	2027-03-30 (estimated)
Updated on ClinicalTrials.gov	2026-01-16